Takeda’s Ninlaro capsules now available in the US
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
List view / Grid view
News
FDA approves Roche’s Alecensa for ALK-positive NSCLC
14 December 2015 | By Victoria White
Alecensa (alectinib) is approved for patients whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib)...
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
NICE says ‘yes’ to heart failure drug sacubitril valsartan
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
NICE changes decision on AstraZeneca’s olaparib
11 December 2015 | By Victoria White
NICE intends to recommend Lynparza (olaparib) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer after AstraZeneca provided more information on the drug...
New data for Eisai’s eribulin presented at SABCS
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
NICE recommends enzalutamide; consults on abiraterone
11 December 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has published draft guidance on two prostate cancer treatments - enzalutamide and abiraterone...
Oxygen-enhanced MRI detects hypoxia within tumours
10 December 2015 | By Victoria White
Teams at The University of Manchester and The Institute of Cancer Research, London, have described detailed development of oxygen-enhanced magnetic resonance imaging (MRI) technology to map areas of oxygen deprivation within tumours.
Immunology treatment market to expand to $74.2b by 2022
10 December 2015 | By Victoria White
According to business intelligence provider GBI Research, the global immunology treatment market is set to expand from $61.5 billion in 2015 to reach $74.2 billion in 2022...
PSL support Singapore increasing pharmaceutical manufacturing
10 December 2015 | By PSL
Powder Systems Limited (PSL), an international award-winning manufacturer of filtration, drying and high containment isolators for the pharmaceutical and biopharmaceutical industries, recently delivered several advanced process installations in Singapore...
Lilly and Merck expand their immuno-oncology collaboration
10 December 2015 | By Victoria White
The companies are to evaluate Lilly’s abemaciclib (LY2835219) and Merck’s Keytruda (pembrolizumab) in a Phase I study across multiple tumour types...
cFDA announces big regulatory policy changes in China
10 December 2015 | By Victoria White
According to PaizaBio, a company focused on helping Western-based pharmaceutical companies manufacture drugs in China for the Chinese market, the new policies will impact both Chinese and Western pharmaceutical companies...
Novo Nordisk submits NDA for faster-acting insulin aspart
10 December 2015 | By Victoria White
Faster-acting insulin aspar is an investigational mealtime insulin developed by Novo Nordisk for the control of blood sugar levels in adults with type 1 and type 2 diabetes...
FDA approves Vonvendi for the treatment of von Willebrand Disease
9 December 2015 | By Victoria White
Vonvendi [von Willebrand factor (Recombinant)] is the first and only recombinant treatment for adults living with von Willebrand Disease (VWD)...
FDA approves Alexion’s Kanuma for LAL deficiency
9 December 2015 | By Victoria White
Kanuma (sebelipase alfa) has been approved for the treatment of patients with a diagnosis of lysosomal acid lipase deficiency (LAL-D)...
